MEDSIR
@medsir.bsky.social
Bring your idea to life💡Creating successful IITs & optimal drug development📊Medica Scientia Innovation Research🇪🇸🇺🇸
www.medsir.org
www.medsir.org
📢 New publication in Nature Medicine! The phase 2 #ATRACTIB trial tested atezolizumab + paclitaxel + bevacizumab as 1L for advanced TNBC, regardless of PD-L1 status.
🕒 Median PFS: 11 months
🎯 ORR: 63%
🔗 Read the full article here 👉🏼
www.nature.com/articles/s41...
#BreastCancer
🕒 Median PFS: 11 months
🎯 ORR: 63%
🔗 Read the full article here 👉🏼
www.nature.com/articles/s41...
#BreastCancer
June 5, 2025 at 7:47 AM
📢 New publication in Nature Medicine! The phase 2 #ATRACTIB trial tested atezolizumab + paclitaxel + bevacizumab as 1L for advanced TNBC, regardless of PD-L1 status.
🕒 Median PFS: 11 months
🎯 ORR: 63%
🔗 Read the full article here 👉🏼
www.nature.com/articles/s41...
#BreastCancer
🕒 Median PFS: 11 months
🎯 ORR: 63%
🔗 Read the full article here 👉🏼
www.nature.com/articles/s41...
#BreastCancer
#MEDSIRatASCO
Dr. Tim Robinson breaks down the #WINBtrial, a study aiming to boost the effectiveness of sacituzumab/govitecan in breast cancer (TNBC & HR+). Despite its promise, many patients don't respond or progress quickly.
Dr. Tim Robinson breaks down the #WINBtrial, a study aiming to boost the effectiveness of sacituzumab/govitecan in breast cancer (TNBC & HR+). Despite its promise, many patients don't respond or progress quickly.
June 3, 2025 at 1:35 PM
#MEDSIRatASCO
Dr. Tim Robinson breaks down the #WINBtrial, a study aiming to boost the effectiveness of sacituzumab/govitecan in breast cancer (TNBC & HR+). Despite its promise, many patients don't respond or progress quickly.
Dr. Tim Robinson breaks down the #WINBtrial, a study aiming to boost the effectiveness of sacituzumab/govitecan in breast cancer (TNBC & HR+). Despite its promise, many patients don't respond or progress quickly.
Dr. María Gion presented #WINBtrial results, a phase Ib/II trial in pretreated HR+/HER2- & TNBC.
📌Sacituzumab govitecan + Debio 0123, a selective, brain-penetrant WEE1 inhibitor.
💡Phase Ib sets dose for phase II, aiming tumor regression.
📌Sacituzumab govitecan + Debio 0123, a selective, brain-penetrant WEE1 inhibitor.
💡Phase Ib sets dose for phase II, aiming tumor regression.
June 3, 2025 at 11:48 AM
Dr. María Gion presented #WINBtrial results, a phase Ib/II trial in pretreated HR+/HER2- & TNBC.
📌Sacituzumab govitecan + Debio 0123, a selective, brain-penetrant WEE1 inhibitor.
💡Phase Ib sets dose for phase II, aiming tumor regression.
📌Sacituzumab govitecan + Debio 0123, a selective, brain-penetrant WEE1 inhibitor.
💡Phase Ib sets dose for phase II, aiming tumor regression.
#MEDSIRatASCO
Day 4!
Isabel Tundidor shares how we combine hard work, science & collaboration during these intense (but rewarding) days.
👉🏼 www.youtube.com/shorts/Qxsac...
#ASCO25 #MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Day 4!
Isabel Tundidor shares how we combine hard work, science & collaboration during these intense (but rewarding) days.
👉🏼 www.youtube.com/shorts/Qxsac...
#ASCO25 #MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
#MEDSIRatASCO
YouTube video by MEDSIR
www.youtube.com
June 2, 2025 at 5:31 PM
#MEDSIRatASCO
Day 4!
Isabel Tundidor shares how we combine hard work, science & collaboration during these intense (but rewarding) days.
👉🏼 www.youtube.com/shorts/Qxsac...
#ASCO25 #MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Day 4!
Isabel Tundidor shares how we combine hard work, science & collaboration during these intense (but rewarding) days.
👉🏼 www.youtube.com/shorts/Qxsac...
#ASCO25 #MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
#GoodMorning MEDSIR
Today we're presenting the posters for #ADELAtrial and #WINBtrial in Hall A, from 9:00 to 12:00 (GMT-5).
📍 WINB: #479b
📍 ADELA: #103b
👉🏼 medsir.org/events/asco2...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Today we're presenting the posters for #ADELAtrial and #WINBtrial in Hall A, from 9:00 to 12:00 (GMT-5).
📍 WINB: #479b
📍 ADELA: #103b
👉🏼 medsir.org/events/asco2...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
June 2, 2025 at 1:59 PM
#GoodMorning MEDSIR
Today we're presenting the posters for #ADELAtrial and #WINBtrial in Hall A, from 9:00 to 12:00 (GMT-5).
📍 WINB: #479b
📍 ADELA: #103b
👉🏼 medsir.org/events/asco2...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Today we're presenting the posters for #ADELAtrial and #WINBtrial in Hall A, from 9:00 to 12:00 (GMT-5).
📍 WINB: #479b
📍 ADELA: #103b
👉🏼 medsir.org/events/asco2...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
#MEDSIRatASCO
Carmen Mora, from BD team, shares updates from day 2 at #ASCO25. Key meetings, global collaborations, and science in action. Let’s keep it going! 🚀
👉🏼 www.youtube.com/shorts/jcVK6...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Carmen Mora, from BD team, shares updates from day 2 at #ASCO25. Key meetings, global collaborations, and science in action. Let’s keep it going! 🚀
👉🏼 www.youtube.com/shorts/jcVK6...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
#MEDSIRatASCO
YouTube video by MEDSIR
www.youtube.com
May 31, 2025 at 9:25 PM
#MEDSIRatASCO
Carmen Mora, from BD team, shares updates from day 2 at #ASCO25. Key meetings, global collaborations, and science in action. Let’s keep it going! 🚀
👉🏼 www.youtube.com/shorts/jcVK6...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Carmen Mora, from BD team, shares updates from day 2 at #ASCO25. Key meetings, global collaborations, and science in action. Let’s keep it going! 🚀
👉🏼 www.youtube.com/shorts/jcVK6...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
#MEDSIRatASCO
On Day 1 of #ASCO25, one of the highlights for #MEDSIR was without a doubt the oral presentation of #TUXEDO3trial, exploring patritumab deruxtecan (HER3-DXd) in patients with very limited treatment options.
🎥 Watch Dr. Preusser explain more 👇
www.youtube.com/watch?v=bjyy...
On Day 1 of #ASCO25, one of the highlights for #MEDSIR was without a doubt the oral presentation of #TUXEDO3trial, exploring patritumab deruxtecan (HER3-DXd) in patients with very limited treatment options.
🎥 Watch Dr. Preusser explain more 👇
www.youtube.com/watch?v=bjyy...
#MEDSIRatASCO - #TUXEDO3trial
YouTube video by MEDSIR
www.youtube.com
May 31, 2025 at 3:35 PM
#MEDSIRatASCO
On Day 1 of #ASCO25, one of the highlights for #MEDSIR was without a doubt the oral presentation of #TUXEDO3trial, exploring patritumab deruxtecan (HER3-DXd) in patients with very limited treatment options.
🎥 Watch Dr. Preusser explain more 👇
www.youtube.com/watch?v=bjyy...
On Day 1 of #ASCO25, one of the highlights for #MEDSIR was without a doubt the oral presentation of #TUXEDO3trial, exploring patritumab deruxtecan (HER3-DXd) in patients with very limited treatment options.
🎥 Watch Dr. Preusser explain more 👇
www.youtube.com/watch?v=bjyy...
#GoodMorning MEDSIR!
Day 2 at #ASCO25 kicks off with what drives us most: teamwork, planning, and purpose. Meetings, connections, and new opportunities await. Let’s go! 🚀
👉🏼 Stay tuned: lnkd.in/dkDs-bp4
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Day 2 at #ASCO25 kicks off with what drives us most: teamwork, planning, and purpose. Meetings, connections, and new opportunities await. Let’s go! 🚀
👉🏼 Stay tuned: lnkd.in/dkDs-bp4
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
May 31, 2025 at 1:38 PM
#GoodMorning MEDSIR!
Day 2 at #ASCO25 kicks off with what drives us most: teamwork, planning, and purpose. Meetings, connections, and new opportunities await. Let’s go! 🚀
👉🏼 Stay tuned: lnkd.in/dkDs-bp4
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Day 2 at #ASCO25 kicks off with what drives us most: teamwork, planning, and purpose. Meetings, connections, and new opportunities await. Let’s go! 🚀
👉🏼 Stay tuned: lnkd.in/dkDs-bp4
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
#MEDSIRatASCO
Have you seen our exclusive newsletter from #ASCO25?
👉 Special Guest: Dr. Matthias Preusser
🗣️ Talking about #TUXEDO3trial, presented at
@ascocancer.bsky.social and published in Nature Medicine.
👉🏼 Click here and don’t miss it: www.linkedin.com/pulse/10-yea...
Have you seen our exclusive newsletter from #ASCO25?
👉 Special Guest: Dr. Matthias Preusser
🗣️ Talking about #TUXEDO3trial, presented at
@ascocancer.bsky.social and published in Nature Medicine.
👉🏼 Click here and don’t miss it: www.linkedin.com/pulse/10-yea...
10 Years From Now In Oncology
QUICK READ Welcome to '10 Years from Now in Oncology', MEDSIR Linkedin Newsletter TUXEDO-3 Presentation at ASCO 2025 Special Guest: Exclusive Interview with Dr. Matthias Preusser, on TUXEDO-3, an oral...
www.linkedin.com
May 31, 2025 at 9:26 AM
#MEDSIRatASCO
Have you seen our exclusive newsletter from #ASCO25?
👉 Special Guest: Dr. Matthias Preusser
🗣️ Talking about #TUXEDO3trial, presented at
@ascocancer.bsky.social and published in Nature Medicine.
👉🏼 Click here and don’t miss it: www.linkedin.com/pulse/10-yea...
Have you seen our exclusive newsletter from #ASCO25?
👉 Special Guest: Dr. Matthias Preusser
🗣️ Talking about #TUXEDO3trial, presented at
@ascocancer.bsky.social and published in Nature Medicine.
👉🏼 Click here and don’t miss it: www.linkedin.com/pulse/10-yea...
#MEDSIRatASCO
Major milestone at #ASCO25!
We presented the #TUXEDO3trial led by Dr. Matthias Preusser with Universität Wien as an oral presentation. The Phase II trial tested HER3-DXd in patients with brain mets & leptomeningeal disease.
Major milestone at #ASCO25!
We presented the #TUXEDO3trial led by Dr. Matthias Preusser with Universität Wien as an oral presentation. The Phase II trial tested HER3-DXd in patients with brain mets & leptomeningeal disease.
May 30, 2025 at 10:22 PM
#MEDSIRatASCO
Major milestone at #ASCO25!
We presented the #TUXEDO3trial led by Dr. Matthias Preusser with Universität Wien as an oral presentation. The Phase II trial tested HER3-DXd in patients with brain mets & leptomeningeal disease.
Major milestone at #ASCO25!
We presented the #TUXEDO3trial led by Dr. Matthias Preusser with Universität Wien as an oral presentation. The Phase II trial tested HER3-DXd in patients with brain mets & leptomeningeal disease.
Reposted by MEDSIR
Bring Your Research Ideas to Life — Meet with MEDSIR @wearemedsir at #ASCO25 to Get Started! 👉 buff.ly/BHKdQ7I
MEDSIR, a global oncology research company that designs & runs innovative, patient-focused clinical trials. Book a meeting at ASCO & explore how you can work together & advance your ideas
MEDSIR, a global oncology research company that designs & runs innovative, patient-focused clinical trials. Book a meeting at ASCO & explore how you can work together & advance your ideas
May 27, 2025 at 11:21 AM
Bring Your Research Ideas to Life — Meet with MEDSIR @wearemedsir at #ASCO25 to Get Started! 👉 buff.ly/BHKdQ7I
MEDSIR, a global oncology research company that designs & runs innovative, patient-focused clinical trials. Book a meeting at ASCO & explore how you can work together & advance your ideas
MEDSIR, a global oncology research company that designs & runs innovative, patient-focused clinical trials. Book a meeting at ASCO & explore how you can work together & advance your ideas
#MEDSIRatASCO
Our BD Manager, Aurelio del Pino, shares how we're expanding at #ASCO25, connecting with key players & forging new partnerships to drive clinical research.
💬 Hit play & join us: medsir.org/events/asco2...
#MEDSIRLive #MedicalResearch #CancerCare #Innovation
@ascocancer.bsky.social
Our BD Manager, Aurelio del Pino, shares how we're expanding at #ASCO25, connecting with key players & forging new partnerships to drive clinical research.
💬 Hit play & join us: medsir.org/events/asco2...
#MEDSIRLive #MedicalResearch #CancerCare #Innovation
@ascocancer.bsky.social
May 30, 2025 at 8:58 PM
#MEDSIRatASCO
Our BD Manager, Aurelio del Pino, shares how we're expanding at #ASCO25, connecting with key players & forging new partnerships to drive clinical research.
💬 Hit play & join us: medsir.org/events/asco2...
#MEDSIRLive #MedicalResearch #CancerCare #Innovation
@ascocancer.bsky.social
Our BD Manager, Aurelio del Pino, shares how we're expanding at #ASCO25, connecting with key players & forging new partnerships to drive clinical research.
💬 Hit play & join us: medsir.org/events/asco2...
#MEDSIRLive #MedicalResearch #CancerCare #Innovation
@ascocancer.bsky.social
#MEDSIRatASCO
Educational sessions are underway and our team is already in Chicago! Want to meet with us at #ASCO25? Schedule your meeting here 👉 medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Educational sessions are underway and our team is already in Chicago! Want to meet with us at #ASCO25? Schedule your meeting here 👉 medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
May 30, 2025 at 6:38 PM
#MEDSIRatASCO
Educational sessions are underway and our team is already in Chicago! Want to meet with us at #ASCO25? Schedule your meeting here 👉 medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Educational sessions are underway and our team is already in Chicago! Want to meet with us at #ASCO25? Schedule your meeting here 👉 medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
#GoodMorning MEDSIR! Big day ahead with the oral presentation of our study #TUXEDO3trial
🕒 4:21–4:33 PM CDT
👨⚕️ Dr. Matthias Preusser
📍 S100bc | CNS Tumors Session
Let’s connect in Chicago: medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
🕒 4:21–4:33 PM CDT
👨⚕️ Dr. Matthias Preusser
📍 S100bc | CNS Tumors Session
Let’s connect in Chicago: medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
May 30, 2025 at 2:48 PM
#GoodMorning MEDSIR! Big day ahead with the oral presentation of our study #TUXEDO3trial
🕒 4:21–4:33 PM CDT
👨⚕️ Dr. Matthias Preusser
📍 S100bc | CNS Tumors Session
Let’s connect in Chicago: medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
🕒 4:21–4:33 PM CDT
👨⚕️ Dr. Matthias Preusser
📍 S100bc | CNS Tumors Session
Let’s connect in Chicago: medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
#MEDSIRatASCO
@ascocancer.bsky.social 2025 kicks off today! We'll be sharing updates on #MEDSIR's participation in the most important oncology congress of the year.
Stay tuned! 👀
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
@ascocancer.bsky.social 2025 kicks off today! We'll be sharing updates on #MEDSIR's participation in the most important oncology congress of the year.
Stay tuned! 👀
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
May 30, 2025 at 12:23 PM
#MEDSIRatASCO
@ascocancer.bsky.social 2025 kicks off today! We'll be sharing updates on #MEDSIR's participation in the most important oncology congress of the year.
Stay tuned! 👀
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
@ascocancer.bsky.social 2025 kicks off today! We'll be sharing updates on #MEDSIR's participation in the most important oncology congress of the year.
Stay tuned! 👀
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
#MEDSIRatASCO is almost here!
Our Scientific Impact Manager, Jose Rodríguez Morató, has a quick message for you.
Let’s connect in Chicago and talk science!
More on our #ASCO25 plans 👉🏼 www.medsir.org/events/asco2...
#ASCO25 #MedicalResearch #CancerCare #Innovation
Our Scientific Impact Manager, Jose Rodríguez Morató, has a quick message for you.
Let’s connect in Chicago and talk science!
More on our #ASCO25 plans 👉🏼 www.medsir.org/events/asco2...
#ASCO25 #MedicalResearch #CancerCare #Innovation
May 26, 2025 at 9:11 AM
#MEDSIRatASCO is almost here!
Our Scientific Impact Manager, Jose Rodríguez Morató, has a quick message for you.
Let’s connect in Chicago and talk science!
More on our #ASCO25 plans 👉🏼 www.medsir.org/events/asco2...
#ASCO25 #MedicalResearch #CancerCare #Innovation
Our Scientific Impact Manager, Jose Rodríguez Morató, has a quick message for you.
Let’s connect in Chicago and talk science!
More on our #ASCO25 plans 👉🏼 www.medsir.org/events/asco2...
#ASCO25 #MedicalResearch #CancerCare #Innovation
We are proud to share our latest work, now published in #Cancers 🧬
In this study, we investigated a novel combination of niraparib and aromatase inhibitors for patients with HR+/HER2- advanced breast cancer and germline BRCA mutations, a population with limited treatment options.
In this study, we investigated a novel combination of niraparib and aromatase inhibitors for patients with HR+/HER2- advanced breast cancer and germline BRCA mutations, a population with limited treatment options.
May 23, 2025 at 10:52 AM
We are proud to share our latest work, now published in #Cancers 🧬
In this study, we investigated a novel combination of niraparib and aromatase inhibitors for patients with HR+/HER2- advanced breast cancer and germline BRCA mutations, a population with limited treatment options.
In this study, we investigated a novel combination of niraparib and aromatase inhibitors for patients with HR+/HER2- advanced breast cancer and germline BRCA mutations, a population with limited treatment options.
We're excited to share that the #MEDSIR team will be at the @ascocancer.bsky.social with an oral presentation and two posters. We would like to highlight our studies:
May 22, 2025 at 1:24 PM
We're excited to share that the #MEDSIR team will be at the @ascocancer.bsky.social with an oral presentation and two posters. We would like to highlight our studies:
Reposted by MEDSIR
Delighted to host @medsir.bsky.social today at #BeaumontRCSICancerCentre, exploring novel ways to develop & expand investigator initiated trials for cancer in Ireland 🇮🇪, through @cancertrialsie.bsky.social & beyond
Welcome @medsir.bsky.social
@rcsi.bsky.social #LCSM
Welcome @medsir.bsky.social
@rcsi.bsky.social #LCSM
January 30, 2025 at 2:42 PM
Delighted to host @medsir.bsky.social today at #BeaumontRCSICancerCentre, exploring novel ways to develop & expand investigator initiated trials for cancer in Ireland 🇮🇪, through @cancertrialsie.bsky.social & beyond
Welcome @medsir.bsky.social
@rcsi.bsky.social #LCSM
Welcome @medsir.bsky.social
@rcsi.bsky.social #LCSM